Evan J. Lipson Charles G. Drake: Ipilimumab: an Anti-CTLA-4 Antibody for Metastatic Melanoma. In: Clin. Cancer Res. 17. Jahrgang, Nr.22, 2011, S.6958–62, doi:10.1158/1078-0432.CCR-11-1595.
N Engl J Med. 2011 Jun 30;364(26):2517-26. doi:10.1056/NEJMoa1104621. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD.
J Clin Oncol. 2015 Apr 1;33(10):1191-6. doi:10.1200/JCO.2014.56.6018. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD.
